Home/Pipeline/Product 1

Product 1

Not Disclosed

Pre-clinicalActive

Key Facts

Indication

Not Disclosed

Phase

Pre-clinical

Status

Active

Company

Regenovva

About Regenovva

Regennova is a private, preclinical-stage biotech founded in 2015, leveraging a peptide discovery platform to develop immune-modulating therapies for inflammatory conditions like sepsis. The company's core technology involves Apolipoprotein E (ApoE) conjugates, termed APEC, aimed at rebalancing the immune response. While the pipeline remains early-stage with placeholder product descriptions, the company has secured non-dilutive grant funding from entities like the NIH and BARDA, indicating external validation of its scientific approach. Key risks include its preclinical status, undisclosed leadership, and the highly competitive landscape of immunomodulation.

View full company profile

Therapeutic Areas

Sepsis Inflammatory Diseases Stroke

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active